EUVIMEDEUVIMED entdecken
Crossref

Tapentadol Versus Oxycodone for Opioid-Related Adverse Drug Events and Clinical Outcomes After Inpatient Surgery

Shania Liu, Asad E Patanwala, Justine M Naylor, Jennifer A Stevens, Bernadette Bugeja, David Begley, Kok E Khor, Eric Lau, Sam Adie, Jonathan Penm

The Journal of Pain · 2024

DOI: 10.1016/j.jpain.2023.09.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pain, 2024. Verfasst von Shania Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: The University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, Australia; Department of Pharmacy, Prince of Wales Hospital, Sy…. Hauptthemen laut MEDLINE: Analgesics, Opioid, Oxycodone. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Avant Foundation, AGA Research Foundation, Prince of Wales Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxycodone is a commonly prescribed opioid for postoperative pain. However, there has been a marked increase in the use of tapentadol over the previous decade due to a perceived superior safety profile of tapentadol compared to oxycodone. There is limited real-world evidence on the safety of tapentadol compared to oxycodone after surgery. The primary objective was to examine the impact of tapentadol compared to oxycodone use on the incidence of opioid-related adverse drug events after surgery. Data for adult surgical patients receiving tapentadol or oxycodone during hospitalization between January 1, 2018, and December 31, 2021, were collected from electronic medical records of 3 tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events. Patients receiving tapentadol or oxycodone were matched using nearest-neighbour propensity score matching. In the matched cohorts (n = 1,530 vs n = 2,775; mean [standard deviation] age 62.3 [17.0] years vs 61.9 [standard deviation 17.9] years; 43% vs 45% male for the tapentadol vs oxycodone groups, respectively), patients given tapentadol experienced a similar incidence of adverse events overall (14.4%, 220/1,530 vs 12.6%, 349/2,775; P = .100; 95% CI -.35% to 3.95%). Secondary outcomes included an increased risk of delirium (2.7%, 41/1,530 vs 1.3%, 37/2,775), arrhythmias (3.4%, 52/1,530 vs 2.2%, 62/2,775), and length of hospital stay (5 [range 1-201] vs 4 [range 1-226] days) compared with oxycodone use. Further real-world studies are warranted to determine the impact of tapentadol use on a broad range of patient outcomes. PERSPECTIVE: This study provides an early signal that tapentadol use may be associated with an increased risk of some adverse events and a longer length of stay. Further research is needed to examine the impact of tapentadol use on a broad range of patient outcomes in clinical practice settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidOxycodoneAdultHumansMaleMiddle AgedFemaleTapentadolInpatientsPhenols

Stichwörter der Autor:innen

OpioidsOxycodoneSurgeryTapentadol

Substanzen

Analgesics, OpioidTapentadolOxycodonePhenols

Autor:innen und Institutionen

  • The University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, Australia; Department of Pharmacy, Prince of Wales Hospital, Sydney, Australia.
  • The University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, Australia; Department of Pharmacy, Royal Prince Alfred Hospital, Sydney, Australia.
  • Whitlam Orthopaedic Research Centre, Ingham Institute, Sydney, Australia; South Western Sydney School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.
  • School of Clinical Medicine, University of New South Wales Medicine and Health, St Vincent's Clinical School, UNSW Medicine and Health, UNSW Sydney, Sydney, Australia; School of Medicine, University of Notre Dame, Sydne…
  • Department of Pain Management, Prince of Wales Hospital, Sydney, Australia.
  • Department of Pain Management, Prince of Wales Hospital, Sydney, Australia; Prince of Wales Clinical School, School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, Australia.

Förderung

  • Avant Foundation
  • AGA Research Foundation
  • Prince of Wales Hospital Foundation
  • National Health and Medical Research Council
  • University of Sydney

Zitieren

APA

Liu, S., Patanwala, A. E., Naylor, J. M., Stevens, J. A., Bugeja, B., Begley, D., Khor, K. E., Lau, E., Adie, S., & Penm, J. (2024). Tapentadol Versus Oxycodone for Opioid-Related Adverse Drug Events and Clinical Outcomes After Inpatient Surgery. The Journal of Pain. https://doi.org/10.1016/j.jpain.2023.09.007

Vancouver

Liu S, Patanwala AE, Naylor JM, Stevens JA, Bugeja B, Begley D, et al. Tapentadol Versus Oxycodone for Opioid-Related Adverse Drug Events and Clinical Outcomes After Inpatient Surgery. The Journal of Pain. 2024. doi:10.1016/j.jpain.2023.09.007

BibTeX
@article{Liu2024,
  author = {Liu, Shania and Patanwala, Asad E and Naylor, Justine M and Stevens, Jennifer A and Bugeja, Bernadette and Begley, David and Khor, Kok E and Lau, Eric and Adie, Sam and Penm, Jonathan},
  title = {Tapentadol Versus Oxycodone for Opioid-Related Adverse Drug Events and Clinical Outcomes After Inpatient Surgery},
  journal = {The Journal of Pain},
  year = {2024},
  doi = {10.1016/j.jpain.2023.09.007}
}
Kostenlos starten →